Intra-Cellular Therapies (“ITCI”) Stock Soars While Key Clinical Data Not Presented to Shareholders Looks Highly Disappointing

(July 15th, 2015) Biotech stocks have been on fire. And for good reason as numerous life-saving discoveries have come out of small, previously-unknown firms, making their owners rich many times over. But beneath the surface, a number of troubling drug development companies have caught the attention of investors with clinical data that’s dubious at best. With seemingly endless amounts of optimism, these biotech stocks have ridden the wave of investor enthusiam even when the data doesn’t look as promising as the market caps seem to indicate.

Read more

All You Ever Wanted to Know About Retrophin But Were Afraid to Ask

(June 2nd, 2014) Humans, like atoms, abhor unsteady states of existence. Just like electron transport gravitates towards a steady-state, people gravitate towards peaceful lands and away from battleground areas. Read more

Know What to Buy When Putin Comes Knocking

So Putin rolls a bunch of tanks up to the Ukrainian border and the market slides a percent or so. In any other market that would be considered a yawn. But here in the good ‘ol US of A, where the average active investor can barely remember the dog days of ’08, few traders seem to have the skill set necessary to maneuver in a down market. Having done this for 20+ years, I thought it would be helpful to share my trading tips for when war comes knocking.
Read more

New Corporate Name & Direction

Tuesday January 28, 8:05 am ET

NEW YORK, Feb. 6 /Businesswire/ — Little Bear Investments LLC (“Little Bear”, or the “Company”) announced today that it has changed its name from Zackfoot Investments LLC. Formerly the Company was known for investments in mainly privately held companies with a slant towards New York-area technology businesses.

Going forward, Little Bear will focus on the tremendous value available in the public markets since the market’s swoon in early 2000. The Company will look to acquire minority or majority stakes of companies valued by the markets at a discount to the target company’s cash, marketable securities and historical low multiple to cash flow.

” Concentration is my motto – first honesty, then industry, then concentration. ” Andrew Carnegie